⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596823 | 0.81 | — | — | |
| SCHEMBL970948 | 0.79 | — | — | |
| SCHEMBL5376 | 0.79 | — | — | |
| SCHEMBL8124733 | 0.76 | TRIM24 (0.41) | — | |
| SCHEMBL13800327 | 0.71 | — | — | |
| SCHEMBL771545 | 0.69 | — | — | |
| SCHEMBL596895 | 0.65 | — | — | |
| SCHEMBL2919169 | 0.65 | — | — | |
| SCHEMBL517940 | 0.65 | — | — | |
| SCHEMBL2916408 | 0.62 | BRD4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116744932-A | Preparation method of chiral oxazine compound | 福建广生中霖生物科技有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-20230183263-A1 | COMBINATION FOR TREATING HEPATITIS B | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-15 | — | — | US | claimed |
| EP-4151220-A1 | COMBINATION FOR TREATING HEPATITIS B | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-03-22 | — | — | EP | claimed |
| CN-115515595-A | Combination for treating hepatitis B | 福建广生中霖生物科技有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | claimed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | claimed |
| EP-3590942-B1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-06-09 | — | — | EP | claimed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| US-11008331-B2 | Hepatitis B virus surface antigen inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | claimed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | claimed |
| EP-0354686-A1 | A process for the enantiospecific synthesis of intermediates for hexahydro-benzo[d] naphto[2,1-b] azepines | SCHERING CORPORATION (US) | 1990-02-14 | — | — | EP | claimed |
| WO-1990000853-A2 | METHOD OF TREATING NEUROLOGICAL DISORDERS | SCHERING CORPORATION (US) | 1990-02-08 | — | — | WO | claimed |
| EP-0351733-A1 | Use of 2,3,4,5-tetrahydro-1H-3-benzazepines in the treatment of neurological disorders | SCHERING CORPORATION (US) | 1990-01-24 | — | — | EP | claimed |
| WO-1989000561-A1 | FUSED BENZAZEPINES | SCHERING CORPORATION (US) | 1989-01-26 | — | — | WO | claimed |
| EP-0299101-A1 | Fused benzazepines | SCHERING CORPORATION (US) | 1989-01-18 | — | — | EP | claimed |
| EP-0254737-A1 | FUSED BENZAZEPINES. | SCHERING CORP (US) | 1988-02-03 | — | — | EP | claimed |
| WO-1987004430-A2 | FUSED BENZAZEPINES | SCHERING CORPORATION (US) | 1987-07-30 | — | — | WO | claimed |
| EP-0230270-A2 | Fused benzazepines | SCHERING CORPORATION (US) | 1987-07-29 | — | — | EP | claimed |
| US-4272617-A | Immobilization of enzymes or bacteria cells | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1981-06-09 | — | — | US | claimed |
| EP-0005299-A1 | Substituted 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | claimed |